Fausto Petrelli1, Sandro Barni. 1. Azienda Ospedaliera di Treviglio, UO Oncologia medica, Treviglio, Italia. faupe@libero.it
Abstract
BACKGROUND: In HER2+ MBC, continuing trastuzumab (T) after the progression during a first-line T-based regimen, represents 1 of the possible strategies, even if few data from randomized trials exist in this setting. MATERIALS AND METHODS: The authors have performed a systematic review through PubMed, including all prospective and retrospective publications exploring the efficacy of a T-based second-line therapy in HER2+ MBC patients treated beyond progression with a first-line T-containing treatment. Pooled estimates of the RR, TTP, and OS were calculated. RESULTS: A total of 29 studies (4 randomized controlled phase III trials, 2 observational studies, 8 prospective nonrandomized trials, and 15 retrospective case series) were retrieved for a total of 2618 patients. All were treated with a second-line, T-based treatment beyond progression with a first-line T-based chemotherapy. Overall, the median RR, TTP, and OS obtained from the selected articles were 28.7%, 7, and 24 months. CONCLUSIONS: This pooled analysis confirms that continuing T beyond the first progression continues to be 1 of the effective and preferred choices in HER2+ MBC, failing a (T-based) first-line regimen.
BACKGROUND: In HER2+ MBC, continuing trastuzumab (T) after the progression during a first-line T-based regimen, represents 1 of the possible strategies, even if few data from randomized trials exist in this setting. MATERIALS AND METHODS: The authors have performed a systematic review through PubMed, including all prospective and retrospective publications exploring the efficacy of a T-based second-line therapy in HER2+ MBCpatients treated beyond progression with a first-line T-containing treatment. Pooled estimates of the RR, TTP, and OS were calculated. RESULTS: A total of 29 studies (4 randomized controlled phase III trials, 2 observational studies, 8 prospective nonrandomized trials, and 15 retrospective case series) were retrieved for a total of 2618 patients. All were treated with a second-line, T-based treatment beyond progression with a first-line T-based chemotherapy. Overall, the median RR, TTP, and OS obtained from the selected articles were 28.7%, 7, and 24 months. CONCLUSIONS: This pooled analysis confirms that continuing T beyond the first progression continues to be 1 of the effective and preferred choices in HER2+ MBC, failing a (T-based) first-line regimen.
Authors: Eva Negri; Alberto Zambelli; Matteo Franchi; Marta Rossi; Martina Bonifazi; Giovanni Corrao; Lorenzo Moja; Carlo Zocchetti; Carlo La Vecchia Journal: Oncologist Date: 2014-10-29
Authors: Humaid O Al-Shamsi; Yazan Fahmawi; Ibrahim Dahbour; Aziz Tabash; Jane E Rogers; Jeannette Elizabeth Mares; Mariela A Blum; Jeannelyn Estrella; Aurelio Matamoros; Tara Sagebiel; Catherine E Devine; Brian D Badgwell; Quan D Lin; Prajnan Das; Jaffer A Ajani Journal: J Gastrointest Oncol Date: 2016-08
Authors: Otto Metzger-Filho; Evandro de Azambuja; Marion Procter; Magalie Krieguer; Ian Smith; Jose Baselga; David Cameron; Michael Untch; Christian Jackisch; Richard Bell; Luca Gianni; Aron Goldhirsch; Martine Piccart; Richard D Gelber Journal: Breast Cancer Res Treat Date: 2015-12-26 Impact factor: 4.872
Authors: Leonidas Apostolidis; Jan Pfeiffenberger; Daniel Gotthardt; Boris Radeleff; Arianeb Mehrabi; Peter Schemmer; Dirk Jäger; Peter Schirmacher; Wolfgang Stremmel; Henning Schulze-Bergkamen; Christoph Springfeld; Karl Heinz Weiss Journal: Gastrointest Tumors Date: 2018-04-11
Authors: Jennifer J Wheler; Johnique T Atkins; Filip Janku; Stacy L Moulder; Roman Yelensky; Philip J Stephens; Razelle Kurzrock Journal: BMC Cancer Date: 2015-05-29 Impact factor: 4.430
Authors: Wolfgang Janni; Tomasz Sarosiek; Boguslawa Karaszewska; Joanna Pikiel; Elzbieta Staroslawska; Piotr Potemski; Christoph Salat; Etienne Brain; Christian Caglevic; Kathryn Briggs; Michelle Desilvio; Luca Marini; Christos Papadimitriou Journal: Breast Cancer Res Treat Date: 2014-01-09 Impact factor: 4.872